Brian R Untch
Overview
Explore the profile of Brian R Untch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nacev B, Sanchez-Vega F, Smith S, Antonescu C, Rosenbaum E, Shi H, et al.
Nat Commun
. 2022 Jun;
13(1):3405.
PMID: 35705560
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes,...
12.
Zhang L, Lubin D, Sinard J, Dickson B, Antonescu C, Wu H, et al.
Head Neck Pathol
. 2022 Feb;
16(3):716-727.
PMID: 35218514
Primary mesenchymal tumors of the thyroid gland are extremely rare, with only case reports and small case series documented in the English literature, many of which were published prior to...
13.
Dermawan J, Vanderbilt C, Chang J, Untch B, Singer S, Chi P, et al.
Genes Chromosomes Cancer
. 2022 Feb;
61(7):412-419.
PMID: 35170141
Genetic alterations in FGF/FGFR pathway are infrequent in gastrointestinal stromal tumors (GIST), with rare cases of quadruple wildtype GISTs harboring FGFR1 gene fusions and mutations. Additionally, FGF/FGFR overexpression was shown...
14.
Xu B, Fuchs T, Ahmadi S, Alghamdi M, Alzumaili B, Bani M, et al.
J Clin Oncol
. 2021 Nov;
40(1):96-104.
PMID: 34731032
Purpose: Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor (NET) arising from the calcitonin-producing C cells. Unlike other NETs, there is no widely accepted pathologic grading scheme. In 2020,...
15.
Lee M, Untch B, Xu B, Ghossein R, Han C, Kuo F, et al.
Mol Cancer Res
. 2021 Oct;
20(1):45-55.
PMID: 34635506
Targeted inhibition of BRAF V600E achieves tumor control in a subset of advanced thyroid tumors. Nearly all tumors develop resistance, and some have been observed to subsequently undergo dedifferentiation. The...
16.
Spanheimer P, Ganly I, Chou J, Capanu M, Nigam A, Ghossein R, et al.
Ann Surg Oncol
. 2021 Mar;
28(11):6572-6579.
PMID: 33748897
Background: Patients with medullary thyroid carcinoma (MTC) often receive lateral lymph node dissection with total thyroidectomy when calcitonin levels are elevated, even in the absence of structural disease, but the...
17.
Vos E, Grewal R, Russo A, Reidy-Lagunes D, Untch B, Gavane S, et al.
J Surg Oncol
. 2020 Sep;
122(8):1821-1826.
PMID: 32914407
Background And Objectives: F-fluorodeoxyglucose positron emission tomography/computed tomography ( F-FDG-PET/CT) parameters may help distinguish malignant from benign adrenal tumors, but few have been externally validated or determined based on definitive...
18.
Alzumaili B, Xu B, Spanheimer P, Tuttle R, Sherman E, Katabi N, et al.
Mod Pathol
. 2020 Apr;
33(9):1690-1701.
PMID: 32313184
Medullary thyroid carcinoma (MTC) is a rare nonfollicular cell-derived tumor. A robust grading system may help better stratify patients at risk for recurrence and death from disease. In total, 144...
19.
Raj N, Zheng Y, Kelly V, Katz S, Chou J, Do R, et al.
J Clin Oncol
. 2019 Oct;
38(1):71-80.
PMID: 31644329
Purpose: Adrenocortical carcinomas (ACC) are rare and aggressive malignancies with limited treatment options. This study was undertaken to evaluate the immunogenicity of ACC. Patients And Methods: Patients with advanced ACC...
20.
Spanheimer P, Ganly I, Chou J, Capanu M, Ghossein R, Tuttle R, et al.
Ann Surg Oncol
. 2019 Sep;
26(13):4423-4429.
PMID: 31549322
Introduction: Long-term outcomes after curative resection in patients with germline RET mutations and medullary thyroid cancer (MTC) are highly variable and mutation-specific oncologic outcomes are not well-described. Methods: Sixty-six patients...